BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 36275718)

  • 1.
    Ge X; Xu M; Cheng T; Hu N; Sun P; Lu B; Wang Z; Li J
    Front Immunol; 2022; 13():974346. PubMed ID: 36275718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
    Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
    Front Neurol; 2022; 13():977180. PubMed ID: 36353126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CNPY4 is a potential promising prognostic-related biomarker and correlated with immune infiltrates in gliomas.
    Li JW; Huang QR; Mo LG
    Medicine (Baltimore); 2022 Aug; 101(33):e30044. PubMed ID: 35984129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
    Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
    Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-associated fibroblast-associated gene IGFBP2 promotes glioma progression through induction of M2 macrophage polarization.
    Zhang X; Sun X; Guo C; Li J; Liang G
    Am J Physiol Cell Physiol; 2024 Jan; 326(1):C252-C268. PubMed ID: 37982173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma.
    Xu Z; Xu H; Chen X; Huang X; Tian J; Zhao J; Liu B; Shi F; Wu J; Pu J
    Onco Targets Ther; 2023; 16():819-837. PubMed ID: 37873495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAPK4 predicts poor prognosis and facilitates the proliferation and migration of glioma through the AKT/mTOR pathway.
    Ren J; Zheng S; Zhang L; Liu J; Cao H; Wu S; Xu Y; Sun J
    Cancer Med; 2023 May; 12(10):11624-11640. PubMed ID: 36999945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
    Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
    Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NCAPG as a Novel Prognostic Biomarker in Glioma.
    Jiang X; Shi Y; Chen X; Xu H; Liu B; Zhou F; Huang X; Cho WC; Li L; Pu J
    Front Oncol; 2022; 12():831438. PubMed ID: 35280743
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
    J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma.
    Lv L; Zhang Y; Zhao Y; Wei Q; Zhao Y; Yi Q
    Front Cell Neurosci; 2021; 15():704344. PubMed ID: 34335194
    [No Abstract]   [Full Text] [Related]  

  • 17. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma.
    Chai RC; Wang N; Chang YZ; Zhang KN; Li JJ; Niu JJ; Wu F; Liu YQ; Wang YZ
    Cancer Cell Int; 2019; 19():155. PubMed ID: 31171919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
    Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
    Front Oncol; 2021; 11():611038. PubMed ID: 33937022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma.
    Dong T; Zhang B; Zhang R; Wang C; Liu X; Wang F; Hao N; Tan K; Chang YZ
    Front Oncol; 2022; 12():963096. PubMed ID: 36237302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.
    Xu J; Liu F; Li Y; Shen L
    Cell Mol Neurobiol; 2022 Apr; 42(3):709-722. PubMed ID: 32894375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.